|
RRAGA expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.45570000498196E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.24419999858461E-08 |
| Normal-vs-Stage2 |
4.578100E-03 |
| Normal-vs-Stage3 |
7.9004003339378E-10 |
| Normal-vs-Stage4 |
8.64890048468681E-10 |
| Stage1-vs-Stage2 |
3.884200E-01 |
| Stage1-vs-Stage3 |
2.453500E-02 |
| Stage1-vs-Stage4 |
2.637900E-03 |
| Stage2-vs-Stage3 |
3.063800E-02 |
| Stage2-vs-Stage4 |
9.418500E-03 |
| Stage3-vs-Stage4 |
2.743200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.95430030333921E-10 |
| Normal-vs-AfricanAmerican |
2.540600E-03 |
| Normal-vs-Asian |
3.87600000000266E-05 |
| Caucasian-vs-AfricanAmerican |
4.400200E-01 |
| Caucasian-vs-Asian |
2.973800E-01 |
| AfricanAmerican-vs-Asian |
9.913000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.42270001230105E-09 |
| Normal-vs-Female |
1.09859999986028E-08 |
| Male-vs-Female |
2.084000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.40579999863277E-08 |
| Normal-vs-Age(41-60Yrs) |
2.43639999952805E-07 |
| Normal-vs-Age(61-80Yrs) |
1.8828000269977E-09 |
| Normal-vs-Age(81-100Yrs) |
5.724000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.888000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.242300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.131800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.468300E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.422000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.588600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.277360E-01 |
| Classical-VS-Follicular |
9.996400E-01 |
| Classical-VS-Other |
9.330000E-01 |
| Classical-VS-Normal |
4.93439999971201E-09 |
| Tall-VS-Follicular |
1.751040E-01 |
| Tall-VS-Other |
6.416200E-01 |
| Tall-VS-Normal |
2.04999999975364E-07 |
| Follicular-VS-Other |
9.501400E-01 |
| Follicular-VS-Normal |
1.67891999999226E-05 |
| Other-VS-Normal |
2.646200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.39959999940254E-08 |
| Normal-vs-N1 |
1.00380037615366E-10 |
| N0-vs-N1 |
1.764430E-03 |
|
|
